← Back to patent-cliff list
BDB-001 (Eikon Therapeutics)
Tier C — Watch / tradeBDB-001 (Eikon Therapeutics)
Birdie Biopharmaceuticals
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：TLR7, TLR8
Indications (approved)：Non-small cell lung cancer, Melanoma, Lung cancer, Solid tumour
Regional status
US
Phase III
2025-05-22
EU
Phase III
2025-05-22
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of BDB-001 (Eikon Therapeutics)?
Approved indications include: Non-small cell lung cancer, Melanoma, Lung cancer, Solid tumour.
When does the BDB-001 (Eikon Therapeutics) patent expire?
No public expiry year is available for BDB-001 (Eikon Therapeutics) yet; this page updates once verified.
How do I get a quote for BDB-001 (Eikon Therapeutics) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30